VASA SIGNED
Vaccine Against Schistosomiasis for Africa. A Phase I clinical study of the SchistoShield® anti-schistosomiasis vaccine in adults in endemic areas of sub-Saharan Africa
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0VASA project word cloud
Explore the words cloud of the VASA project. It provides you a very rough idea of what is the project "VASA" about.
Project "VASA" data sheet
The following table provides information about the project.
| Coordinator |
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 0 € |
| EC max contribution | 6˙619˙342 € (0%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SC1-2018-Two-Stage-RTD |
| Funding Scheme | RIA-LS |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-06-01 to 2024-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE | UK (CAMBRIDGE) | coordinator | 1˙537˙385.00 |
| 2 | INTERNATIONAL VACCINE INSTITUTE | KR (Seoul) | participant | 1˙217˙823.00 |
| 3 | UNIVERSITY OF ANTANANARIVO | MG (Antananarivo) | participant | 864˙420.00 |
| 4 | TEXAS TECH UNIVERSITY SYSTEM | US (LUBBOCK) | participant | 704˙831.00 |
| 5 | GROUPE DE RECHERCHE ACTION EN SANTE SARL | BF (OUAGADOUGOU) | participant | 643˙812.00 |
| 6 | ACADEMISCH ZIEKENHUIS LEIDEN | NL (LEIDEN) | participant | 612˙856.00 |
| 7 | PAI LIFE SCIENCES INC. | US (WILMINGTON) | participant | 387˙290.00 |
| 8 | GOETEBORGS UNIVERSITET | SE (GOETEBORG) | participant | 350˙000.00 |
| 9 | UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO | BF (OUAGADOUGOU 03) | participant | 259˙672.00 |
| 10 | EBERHARD KARLS UNIVERSITAET TUEBINGEN | DE (TUEBINGEN) | participant | 41˙250.00 |
Map
Project objective
Schistosomiasis is a poverty-related neglected tropical disease, impacting one billion people in 74 countries. Science ranked a schistosomiasis-vaccine as one of the top-10 vaccines urgently needed. Chemotherapy is the preferred method for schistosomiasis control; but the effectiveness of mass-treatment programs is compromised by reinfection requiring regular re-treatment. An efficacious vaccine, with long-lasting protection against all schistosomiasis forms, would impact disease control. We request funding for the clinical development of our SchistoShield®-vaccine (Sm-p80 antigenGLA-SE adjuvant) in Burkina Faso and Madagascar, where Schistosoma mansoni (causing intestinal/hepatic schistosomiasis) and S. haematobium (causing urinary schistosomiasis) are endemic. In baboon studies, SchistoShield® has been effective against all major schistosome species. It is the only vaccine candidate having consistently exhibited potent prophylactic, anti-fecundity, egg-induced pathology resolving, transmission-blocking and therapeutic efficacy. The objectives are to 1) transfer vaccine manufacturing technology for cGMP production to a European manufacturer; 2) assess the safety/immunogenicity of SchistoShield® in a Phase I clinical study in healthy African adults; 3) refine a schistosomiasis human challenge model to identify correlates of protection, innate and adaptive immune signatures, gene expression and the role of antibodies in the prevention/control of Schistosoma infections; and 4) foster a global consortium to advance research on schistosomiasis vaccines and address downstream access constraints in resource-poor settings. The funding requested will allow the clinical development of SchistoShield®. GMP production will be transferred to a European partner. African site research capacity will be improved and epidemiological burden data using novel diagnostic techniques will be used to advance clinical development to Phase 2 and potential future elimination project
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VASA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "VASA" are provided by the European Opendata Portal: CORDIS opendata.